MRNA vs STX

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Aug 06, 2026

MRNA

48.8
AI Score
VS
STX Wins

STX

56.1
AI Score

Investment Advisor Scores

MRNA

49score
Recommendation
HOLD

STX

56score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric MRNA STX Winner
Revenue 534.00M 8.57B STX
Net Income -2.13B 1.89B STX
Net Margin -397.9% 22.1% STX
Operating Income -2.20B 2.54B STX
ROE -31.4% 172.6% STX
ROA -19.4% 21.3% STX
Total Assets 10.96B 8.89B MRNA
Cash 1.72B 1.15B MRNA
Debt/Equity 0.09 3.16 MRNA
Current Ratio 2.29 1.33 MRNA
Free Cash Flow -1.25B 1.99B STX

Relative Price Performance (Last 90 Days)

MRNA 1M: -22.7% · 3M: +21.9% STX 1M: -8.7% · 3M: +6.0%

Current Technical Phase

MRNA

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 50

RSI (14): 50.2 · Price: $59.17

STX

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 46

RSI (14): 46.0 · Price: $812.76

Fundamentals Snapshot

Metric MRNA STX
Market Cap
Forward P/E -11.0 28.5
Trailing P/E 60.2
Revenue (TTM)
Revenue Growth 0.0% 0.5%
Gross Margin -0.7% 0.5%
Operating Margin -5.6% 0.4%
EPS -7.88 14.16
Dividend Yield 0.00%

Frequently Asked Questions

Based on our detailed analysis, STX is currently the stronger investment candidate, winning 7 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.